TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06016972
Drug: Experimental: QLS-111 ophthalmic solution, (0.075%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLS-111 ophthalmic solution, (0.075%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
Study: NCT05203588
Drug: calcium and vitamin D
Normalized name: Wellesse Calcium and Vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcium (≥1·0 g) and vitamin D (≥400 IU).
Study: NCT05993975
Drug: Bupivacain 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine hydrochloride was given without any adjuvant
Study: NCT05226507
Drug: NXP800
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXP800 is an anti-neoplastic, oral small molecule.
Study: NCT06467344
Drug: ACDN-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection.
Study: NCT05280873
Drug: Pirfenidone, methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 2 mg / kg / d+ pirfenidone (starting from 200mg tid, increasing to 600mg tid within one week and maintaining) . Methylprednisolone was reduced according to the researcher's evaluation of the patient's condition and the specific course of treatment was determined.
Study: NCT05477576
Drug: RYZ101
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP3D as determined in Phase 1b
Study: NCT05088876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded withdrawal of regular co-medication with paracetamol
Study: NCT06787144
Drug: ELVN-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally once daily
Study: NCT06634849
Drug: PTT-4256
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral intake of PTT-4256 followed by treatment-free period of 3 days to assess safety, PK and PD. After 72-hr post dose PK sample, first 21day cycle of once daily PTT-4256 will begin to assess DLTs. Cohort 1-3 will receive 10mg, 20mg \& 40mg.
Study: NCT05802394
Drug: Later-line therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Another chemotherapy regimen, targeted therapy, or immunotherapy
Study: NCT06785636
Drug: Cohort 2A (Pocenbrodib monotherapy), Cohort 2B (Pocenbrodib + abiraterone acetate), Cohort 2C (Pocenbrodib + olaparib), Cohort 2D (Pocenbrodib + 177Lu-PSMA-617
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pocenbrodib alone or in combination
Study: NCT05192486
Drug: GNC-038
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion
Study: NCT05230758
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching white round tablet containing excipients only. The placebo tablets will match the active drug as closely as possible in terms of appearance.
Study: NCT05557591
Drug: BNT116
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT116 is administered by IV injection.
Study: NCT05421416
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sugar pill
Study: NCT05875441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 placebo capsules will be administered as a single dose.
Study: NCT06271174
Drug: Profofol and/or Suxaméthonium and/or Sévoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia~Anesthetic induction is performed on a full stomach using :~* Intravenous hypnotic Propofol 2-5 mg/kg~* A rapid-acting intravenous curare Suxamethonium 1 mg/kg~On an empty stomach :~- An intravenous hypnotic Propofol 2 to 5 mg/kg or/and an inhalatory hypnotic, Sevoflurane, as anesthetic co-induction by these 2 agents is generally used in pediatrics.
Study: NCT05957432
Drug: Black Seed Oil Cap/Tab
Normalized name: BLACK SEED OIL CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: possessed anti-H. pylori activity comparable to triple therapy and improved dyspepsia symptoms in infected patients
Study: NCT05957432
Drug: Vonoprazan, Amoxicillin and Clarithromycin
Normalized name: vonoprazan, amoxicillin and clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: H pylori vonoprazan based treatment
Study: NCT06494943
Drug: IBI110
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAG-3 inhibitor
Study: NCT05166889
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.
Study: NCT06126666
Drug: ABL103
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABL103 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in tumor-expansion part will be evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
Study: NCT05462353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets administered orally once daily.
Study: NCT05423691
Drug: CK0804
Approvals — FDA: no, EMA: no, PMDA: no
Description: CK0804 is a cryopreserved, allogeneic T-regulatory cell product that is manipulated to traffic to the bone marrow.
Study: NCT04919369
Drug: Tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05184192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactose monohydrate NF
Study: NCT04513821
Drug: Mino-Lok Therapy (MLT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter. Mino-Lok is made available through this expanded access protocol to patients who otherwise do not qualify for the phase 3 clinical trial (NCT02901717) Other Name: Standard of care antibiotics + Mino-Lok
Study: NCT05765981
Drug: VGN-R09b
Approvals — FDA: no, EMA: no, PMDA: no
Description: VGN-R09b will be injected into bilateral putamen by stereotactic surgery.（Through the SmartFlow Ventricular Cannula or the parenchymal injection tube actually used in the research center）
Study: NCT05156398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo 75mg or 50mg (2 X 25mg) ODT
Study: NCT06040320
Drug: CHP
Normalized name: TRACH SPEAKING VALVE,TRACHPHONE #7707
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (750 mg/m\^2) + doxorubicin (50 mg/m\^2) + prednisone (100 mg days 2-6)
Study: NCT06484062
Drug: Decitabine and Cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04880434
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT05814601
Drug: norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: norepinephrine at a concentration of 5 mcg/ml is preemptively administered
Study: NCT05826535
Drug: IMPT-314
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR T-cell therapy
Study: NCT04888741
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Post transplant cyclophosphamide strategy for GVHD prophylaxis
Study: NCT06798246
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemicitabin and cisplatin
Study: NCT06798246
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1/PD-L1
Study: NCT05480774
Drug: Placebo hard capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject was given orally 2 placebo hard capsules/day for 12 weeks
Study: NCT06234345
Drug: Comparator - Trimbow®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to this group will receive 2 triggering twice a day
Study: NCT05599919
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
Study: NCT04380545
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06037031
Drug: Drug: PF-07923568
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of PF-07923568 administered orally as 4 capsules
Study: NCT04867434
Drug: RZL-012
Approvals — FDA: no, EMA: no, PMDA: no
Description: small synthetic molecule for submental fat reduction
Study: NCT04867434
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04856982
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT04741139
Drug: Acetaminophen and Diphenhydramine Only Product
Normalized name: Acetaminophen and diphenhydramine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using a scheduled medication regimen of diphenhydramine and acetaminophen following IVIG medication to evaluate feasibility of enrollment, medication adherence, side effects related to study medication and IVIG.
Study: NCT06085742
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60mg/m2 PO once a day (21 continuous days)
Study: NCT06085742
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg/m2 PO BID on days 1, 8, and 15
Study: NCT06085742
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825mg/m2 PO BID on days 1-14
Study: NCT05594043
Drug: MK-6598
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05146739
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Give PO or IV
Study: NCT05146739
Drug: Triple Intrathecal Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IT
Study: NCT06460987
Drug: RAS inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive RAS inhibitor treatment as specified in the KDIGO guidelines
Study: NCT06460987
Drug: Immune Suppressant
Normalized name: IMMUNE SUPPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive immune suppressant treatment as specified in the KDIGO guidelines
Study: NCT06109779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV (intravenous) Q3W
Study: NCT06109779
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (Oral) 1250 mg/m2 BID (twice daily) for 2 weeks on/1 week off in 21-day cycles or per local practice
Study: NCT04650269
Drug: Biktarvy 50Mg-200Mg-25Mg Tablet
Normalized name: Biktarvy 50mg-200mg-25mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Biktarvy (50/200/25mg) combination ART by mouth for 6 months
Study: NCT05398679
Drug: Clindamycin Injection
Normalized name: clindamycin Injection
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg/8 hours (maximum 1.800 mg x day) IV
Study: NCT05398679
Drug: Rifampicin Only Product in Oral Dose Form
Normalized name: Rifampicin only product in oral dose form
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,3-0,5 g/12 hours (maximum 1200 mg x day)
Study: NCT05398679
Drug: Rifampicin Only Product in Parenteral Dose Form
Normalized name: Rifampicin only product in parenteral dose form
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,3-0,6 g/12 hours (maximum 1200 mg x day)
Study: NCT05935761
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same as active comparator arms, except placebo dispensed
Study: NCT06336005
Drug: NNC6022-0001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will recieve single ascending dose (SAD) of NNC6022-0001. Dose is given in escalating manner for up to seven cohorts.
Study: NCT06336005
Drug: Placebo (NNC6022-0001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will recieve single ascending dose (SAD) of placebo. Placebo is given in escalating manner for up to seven cohorts
Study: NCT05193396
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: hydrocortisone
Study: NCT05869773
Drug: JZP258
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/ml calcium, magnesium, potassium, and sodium oxybates oral solution
Study: NCT05087992
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI
Study: NCT06154200
Drug: Testosterone gel 4.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone gel applied to eyelids twice per day
Study: NCT06154200
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel applied to eyelids twice per day
Study: NCT06468280
Drug: XELOX Chemotherapy Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin: 130 mg/m² administered via a 3-hour intravenous infusion on D1 of each 3-week cycle.~Capecitabine: 1000 mg/m² taken orally twice daily. The first dose is administered on the evening of D1, and the last dose on the morning of D15, consisting of 2 weeks of treatment and a 1-week break in each 3-week cycle.
Study: NCT06073665
Drug: Levothyroxine Sodium
Normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine dose will depend on dose at baseline and randomization group
Study: NCT05758922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT05869955
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT05106296
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each treatment cycle.
Study: NCT05789797
Drug: Remaxol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remaxol®, solution for infusions, by intravenous drop infusion in the dose of 400 ml/day, on everyday basis for 12 days
Study: NCT05624749
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo s.c. monthly
Study: NCT05107674
Drug: NX-1607
Normalized name: Replesta NX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral NX-1607
Study: NCT05011019
Drug: AL2846 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL2846 is a multi-target receptor tyrosine kinase inhibitor.
Study: NCT04309552
Drug: 18F-FMISO PET
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspected HGG subjects will undergo combined FMISO/FLT dyn-PET at baseline as part of surgical planning. Dyn-PET images will be acquired with staggered FMISO/FLT injections using a lag time of 50 minutes. Preoperatively FMISO/FLT dyn-PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization for HIF-1α, Ki-67, VEGF, EGFR, IDH, and pimonidazole, as well as TERT. FMISO-PET uptake rate, k3, (surrogate for hypoxia) and FLT-PET influx rate, Ki (surrogate for proliferation) will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year.
Study: NCT04309552
Drug: 18F-FLT PET
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspected HGG subjects will undergo combined FMISO/FLT dyn-PET at baseline as part of surgical planning. Dyn-PET images will be acquired with staggered FMISO/FLT injections using a lag time of 50 minutes. Preoperatively FMISO/FLT dyn-PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization for HIF-1α, Ki-67, VEGF, EGFR, IDH, and pimonidazole, as well as TERT. FMISO-PET uptake rate, k3, (surrogate for hypoxia) and FLT-PET influx rate, Ki (surrogate for proliferation) will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year.
Study: NCT06232577
Drug: Hydrocodone
Normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by PO
Study: NCT06003998
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX-4 regimens consist of 85 mg/m2 oxaliplatin plus 200 mg/m2 LV and 5-FU 400 mg/m2 bolus on day 1 followed by 1600 mg/m2 5-FU as a 46-h infusion
Study: NCT05140382
Drug: AZD4573
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4573 will be given intravenously
Study: NCT06124807
Drug: LY3305677
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04031066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion i.v. treatment
Study: NCT06124807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06680661
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (Cy) is one part of the conditioning regimen. 50 mg/kg beginning on day -6.
Study: NCT05526742
Drug: CKD-510 tablet (test)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of CKD-510 will be administered as oral tablet in a fasted state.
Study: NCT05526742
Drug: CKD-510 tablet (test)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of CKD-510 will be administered as oral tablet in a fed state.
Study: NCT06375993
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy for Lymphodepletion
Study: NCT06030622
Drug: C3 (Metformin, Simvastatin, and Digoxin) only
Normalized name: simvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: C3 only (Metformin, Simvastatin, and Digoxin) if patients decline Gemcitabine (Arm 2).
Study: NCT04567732
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of Placebo
Study: NCT05947643
Drug: theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsules dissolved in intranasal irrigation
Study: NCT05947643
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical-appearing lactose capsules dissolved in intranasal irrigation
Study: NCT05065424
Drug: IV Atropine and Fentanyl Premedication Arm
Normalized name: pralidoxime and atropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to the LISA procedure, the blinded bedside nurse will infuse IV Atropine, labelled as Atropine/Placebo, over 1 minute, followed by IV fentanyl, labelled as Fentanyl/Placebo, over 20 minutes in the presence of blinded respiratory therapist and primary team provider.~After medication infusion, a primary team member will perform Less Invasive Surfactant Administration procedure. Infant vital signs, cerebral Near Infrared Spectroscopy values, pain scores will be monitored and recorded during and for 12 hours after the procedure. Level of respiratory support, oxygen requirement and subsequent need for intubation for 24 hours after the procedure will be obtained from the electronic medical record.
Study: NCT05669755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide subcutaneously.
Study: NCT05084235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matches the active drug in appearance, odor and labelling
Study: NCT06379425
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
Study: NCT06379425
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
Study: NCT06630325
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06168461
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule
Study: NCT06630234
Drug: DCC-3009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05806346
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) intravenous administration
Study: NCT05540860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered orally once per day
Study: NCT05040321
Drug: MIB-626
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to either receive MIB-626 or matching placebo. The proposed intervention - targets multiple contributors to the pathology of AD; MIB-626 improves mitochondrial function, bioenergetics, and insulin sensitivity, inhibits A beta accumulation by reducing its synthesis and increasing its clearance, reduces neuroinflammation, exerts neuronal protective effects, and promotes neuronal regeneration and connectivity in preclinical models.
Study: NCT05040321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to receive either the placebo or 1000 mg MIB-626 twice daily orally.
Study: NCT03560583
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10 mg BID
Study: NCT05449132
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching RTX-GRT7039 intra-articular injection.
Study: NCT04748588
Drug: Anti-SARS-CoV-2 mAb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casirivimab/imdesimab 1200mg/1200mg OR sotrovimab 500mg OR bamlanivimab 700mg IV x1.~Casirivimab/imdesimab (REGN) and sotrovimab will be the default agents used (according to local availability) unless both unavailable AND virus strain known to be native or alpha (B.1.1.7) in which case bamlanivimab can be used.